RNA

Atrium Therapeutics

RNA

Attention (50-day avg)0%

Attention rank (50-day avg)#1,741

Bullish sentiment (50-day avg)8%

Price to earnings ratio-2.92

Market capitalization144M

Earnings per share-5.44

Dividend yield (TTM)—

Revenue (annual)18.6M

Net income (annual)-76.7M

Social

What share of all stock conversation is about RNA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Mar 6

Avidity Biosciences, Inc. (RNA) reported $8.01M revenue in its December operational report.
The company expects research and development expenses to increase as it advances clinical programs.
RNA's existing cash and marketable securities are expected to fund operations for at least 12 months.

Generated by AI

Sentiment

Of the messages about RNA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% 0	7.55% -92.45	75.57% -8.76
Bearish	—	100% 0	92.45% +92.45	24.43% +8.76

Bullish· Nov 7

The acquisition of Avidity Biosciences by Novartis is expected to be a win for the spinco, with a fair deal and key talent married with science.
Avidity's early-stage precision cardiology programs will be spun off into a new publicly traded company, offering shareholders a potential new investment opportunity.
The deal is expected to close in the first half of 2026, pending regulatory and shareholder approval, and will see Avidity shareholders receive one share of SpinCo for every ten shares of Avidity they own.

Bearish· Dec 15

The FDA has placed a hold on new participants in Avidity Biosciences' MARINA trial due to an undisclosed serious adverse event.
Avidity Biosciences has two separate offering filings, totaling $350M, which may lead to a significant price drop.
The company's stock has experienced a pattern of "pop and drop," with many analysts predicting a future price decline.

Generated by AI

Topics

Of the messages about RNA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	98.39%	95.83%
Technical Analysis	—	0%	1.61%	1.41%
Analysts	—	0%	0%	2.06%
Controversies	—	0%	0%	0.34%
Earnings	—	0%	0%	0.08%
Macro	—	0%	0%	0.28%

Announcements· Feb 27

Novartis has completed its acquisition of Avidity Biosciences, Inc. (RNA) for $72.00 per share in cash, with an equity value of approximately $12 billion.
The acquisition adds Avidity's muscle-directed AOC platform and three late-stage neuromuscular programs to Novartis, supporting a 2025-2030 net sales CAGR of 5-6% and potential multi-billion-dollar value.
Avidity Biosciences has merged with Novartis AG, becoming an indirect wholly owned subsidiary, and Atrium Therapeutics has launched as a newly independent, publicly traded company with approximately $270 million to advance novel RNA medicines.

Technical Analysis· Dec 14

$RNA is consolidating above R3 after bouncing off S1 on the Open, indicating a potential reversal in the stock's trend.
The stock has a bearish descending triangle formation, with high institutional ownership, which may limit the extent of any potential decline, but could still trade between $16.50 and $17.50 for some time.
$RNA has a BULL COIL formation, with extension targets of 15.90-16 and 16.75-17+, and support levels of 14.15-14.25 and 13.70-13.75, indicating a potential continuation of the stock's upward momentum.

Generated by AI

Community

Of the messages about RNA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	75%	74.39%	63.93%
Newcomers	—	25%	25.61%	36.07%

Regulars· Oct 27

Avidity Biosciences, Inc. ($RNA) has agreed to a $12B acquisition by Novartis ($NVS) in a deal that values RNA at $72/sh, representing a 46% premium over its 10/24 close.
The acquisition will see Novartis gain RNA's neuro pipeline and RNA-targeting delivery platform, including Ab oligo conjugate (AOC) tech, while RNA's cardio assets will be spun off into a new company, SpinCo.
SpinCo will receive $270M in cash and 1 share for every 10 shares of RNA, with the record date for distribution yet to be determined, and RNA's stock price expected to be influenced by the spinoff.

Newcomers· Mar 6

Newcomers are focused on the company's revenue, with one mentioning a specific figure of $8.01M.

Generated by AI

News

Also Discussed

Investors talking about RNA also mention

#	Name	Attention
1	Dyne Therapeutics, Inc.DYN	0%new
2	IDEAYA Biosciences Inc.IDYA	0%-0.01
3	Wave Life Sciences Ltd.WVE	0%+0
4	ETNB - 89bio, Inc.	——
5	Ginkgo Bioworks Holdings, Inc. Class A Common StockDNA	0.02%new
6	uniQure N.V.QURE	0.02%+0.01
7	MTSR - Metsera, Inc.	——
8	Alnylam Pharmaceuticals, Inc.ALNY	0%0
9	RAPT - RAPT Therapeutics, Inc.	——
10	TRML - Tourmaline Bio, Inc.	——

Atrium Therapeutics, Inc.

Healthcare
Biotechnology

Atrium Therapeutics, Inc. is a biopharmaceutical company focused on precision cardiology through targeted RNA therapeutics for heart disease. The company develops therapies designed to deliver ribonucleic acid medicines directly to cardiac tissue, using a proprietary delivery platform that combines tissue-selective targeting with oligonucleotide precision. Its current pipeline centers on rare genetic cardiomyopathies, including ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy. Atrium Therapeutics also advances research programs aimed at additional rare cardiac conditions, reflecting its focus on genetically defined diseases with significant unmet medical need. Based in San Diego, California, Atrium Therapeutics operates as a specialist developer in the broader biotechnology sector, with a business model centered on translating RNA science into potential treatments for inherited heart disorders.

Website

Location

10578 Science Center Drive

San Diego, CA, 92121

United States

Social

What share of all stock conversation is about RNA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Mar 6

Avidity Biosciences, Inc. (RNA) reported $8.01M revenue in its December operational report.
The company expects research and development expenses to increase as it advances clinical programs.
RNA's existing cash and marketable securities are expected to fund operations for at least 12 months.

Generated by AI

Sentiment

Of the messages about RNA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% 0	7.55% -92.45	75.57% -8.76
Bearish	—	100% 0	92.45% +92.45	24.43% +8.76

Bullish· Nov 7

The acquisition of Avidity Biosciences by Novartis is expected to be a win for the spinco, with a fair deal and key talent married with science.
Avidity's early-stage precision cardiology programs will be spun off into a new publicly traded company, offering shareholders a potential new investment opportunity.
The deal is expected to close in the first half of 2026, pending regulatory and shareholder approval, and will see Avidity shareholders receive one share of SpinCo for every ten shares of Avidity they own.

Bearish· Dec 15

The FDA has placed a hold on new participants in Avidity Biosciences' MARINA trial due to an undisclosed serious adverse event.
Avidity Biosciences has two separate offering filings, totaling $350M, which may lead to a significant price drop.
The company's stock has experienced a pattern of "pop and drop," with many analysts predicting a future price decline.

Generated by AI

Topics

Of the messages about RNA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	98.39%	95.83%
Technical Analysis	—	0%	1.61%	1.41%
Analysts	—	0%	0%	2.06%
Controversies	—	0%	0%	0.34%
Earnings	—	0%	0%	0.08%
Macro	—	0%	0%	0.28%

Announcements· Feb 27

Novartis has completed its acquisition of Avidity Biosciences, Inc. (RNA) for $72.00 per share in cash, with an equity value of approximately $12 billion.
The acquisition adds Avidity's muscle-directed AOC platform and three late-stage neuromuscular programs to Novartis, supporting a 2025-2030 net sales CAGR of 5-6% and potential multi-billion-dollar value.
Avidity Biosciences has merged with Novartis AG, becoming an indirect wholly owned subsidiary, and Atrium Therapeutics has launched as a newly independent, publicly traded company with approximately $270 million to advance novel RNA medicines.

Technical Analysis· Dec 14

$RNA is consolidating above R3 after bouncing off S1 on the Open, indicating a potential reversal in the stock's trend.
The stock has a bearish descending triangle formation, with high institutional ownership, which may limit the extent of any potential decline, but could still trade between $16.50 and $17.50 for some time.
$RNA has a BULL COIL formation, with extension targets of 15.90-16 and 16.75-17+, and support levels of 14.15-14.25 and 13.70-13.75, indicating a potential continuation of the stock's upward momentum.

Generated by AI

Community

Of the messages about RNA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	75%	74.39%	63.93%
Newcomers	—	25%	25.61%	36.07%

Regulars· Oct 27

Avidity Biosciences, Inc. ($RNA) has agreed to a $12B acquisition by Novartis ($NVS) in a deal that values RNA at $72/sh, representing a 46% premium over its 10/24 close.
The acquisition will see Novartis gain RNA's neuro pipeline and RNA-targeting delivery platform, including Ab oligo conjugate (AOC) tech, while RNA's cardio assets will be spun off into a new company, SpinCo.
SpinCo will receive $270M in cash and 1 share for every 10 shares of RNA, with the record date for distribution yet to be determined, and RNA's stock price expected to be influenced by the spinoff.

Newcomers· Mar 6

Newcomers are focused on the company's revenue, with one mentioning a specific figure of $8.01M.

Generated by AI

Atrium Therapeutics

Social

Mar 6

Bullish· Nov 7

Bearish· Dec 15

Announcements· Feb 27

Technical Analysis· Dec 14

Regulars· Oct 27

Newcomers· Mar 6

Pharma sector doubles down on AI to slash costs, timelines

Novartis Sees Avidity Drug Fail in Third Setback in a Week

Pharma sector doubles down on AI amid hopes of slashing costs, timelines

Also Discussed

Atrium Therapeutics, Inc.

Company Information

Location

Pharma sector doubles down on AI to slash costs, timelines

Novartis Sees Avidity Drug Fail in Third Setback in a Week

Pharma sector doubles down on AI amid hopes of slashing costs, timelines

Also Discussed

Social

Mar 6

Bullish· Nov 7

Bearish· Dec 15

Announcements· Feb 27

Technical Analysis· Dec 14

Regulars· Oct 27

Newcomers· Mar 6